HIV-2 gp36, Recombinant, His-Tag (Human Immunodeficiency Virus Type 2)
Catalog No : USB-209006
531.05€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | HIV-2 gp36, Recombinant, His-Tag (Human Immunodeficiency Virus Type 2) | ||
|---|---|---|---|
| Catalog No | USB-209006 | ||
| Supplier’s Catalog No | 209006 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant, E. coli | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 64 | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | ~95% (HPLC, SDS-PAGE) | ||
| Form | Supplied as a liquid in 20mM sodium carbonate, pH 9.6, 0.02% sodium azide. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | ~95% (HPLC, SDS-PAGE) | ||
| Description | HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears and vaginal fluids. Immunodeficiency develops more slowly with HIV-2. HIV-2 is less infectious in the early stages of the virus than with HIV-1. The infectiousness of HIV-2 increases as the virus progresses. Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4- independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both membrane- anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain, which is common to many viral and cellular fusion proteins and which seems to drive fusion. HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature (25°C), does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, and is not affected by target membrane glycosphingolipid composition. Source: Recombinant protein corresponding to the sequence of HIV-2 envelope immunodominant regions gp36, fused to a 6X His-tag /chaperone protein at N-terminus., expressed in E. coli. Molecular Weight: ~64kD Specificity: Immunoreactive with all sera of HIV-2 infected individuals. Applications: Suitable for use as an antigen in ELISA and Western Blot, excellent for early detection of HIV seroconvertors with minimal specificity problems. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. | ||
Product Details
© 2020 Imugex All Rights Reserved